カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界のがん診断市場2022年-2031年：検査種類別（腫瘍バイオマーカー検査、画像診断、内視鏡検査、生体検査）、エンドユーザー別

◆英語タイトル：Cancer Diagnostics Market (Test Type: Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy; End-user: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
	◆商品コード：TMR23JN029 ◆発行会社（リサーチ会社）：Transparency Market Research ◆発行日：2022年10月21日 ◆ページ数：190 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥869,250	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,319,250	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,769,250	見積依頼/購入/質問フォーム

★Transparency Market Researchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社の市場調査レポートでは、世界のがん診断市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、検査種類別（腫瘍バイオマーカー検査、画像診断、内視鏡検査、生体検査）分析、用途別（乳がん、肺がん、大腸がん、前立腺がん、その他がん）分析、エンドユーザー別（病院、外来手術センター、診断研究所、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。また、企業情報として、Abbott、Agilent Technologies, Inc.、Applied DNA Sciences、Becton, Dickinson and Company、bioMérieux SA、Eli Lilly and Company、Exact Sciences Corporation、F. Hoffmann-La Roche Ltd.、General Electric Company、Hologic, Inc.、Illumina, Inc.、Menarini Silicon Biosystems、QIAGEN、Siemens Healthcare GmbH、Thermo Fisher Scientific, Inc.などがあります。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界のがん診断市場規模：検査種類別
- 腫瘍バイオマーカー検査の市場規模
- 画像診断の市場規模
- 内視鏡検査の市場規模
- 生体検査の市場規模
・世界のがん診断市場規模：用途別
- 乳がんにおける市場規模
- 肺がんにおける市場規模
- 大腸がんにおける市場規模
- 前立腺がんにおける市場規模
- その他がんにおける市場規模
・世界のがん診断市場規模：エンドユーザー別
- 病院における市場規模
- 外来手術センターにおける市場規模
- 診断研究所における市場規模
- その他エンドユーザーにおける市場規模
・世界のがん診断市場規模：地域別
- 北米のがん診断市場規模
- ヨーロッパのがん診断市場規模
- アジア太平洋のがん診断市場規模
- 中南米のがん診断市場規模
- 中東・アフリカのがん診断市場規模
・競争状況

Cancer Diagnostics Market – Scope of Report
TMR’s report on the global cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cancer diagnostics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cancer diagnostics market.

The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer diagnostics market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market cancer diagnostics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Developments & New Approaches in Cancer Diagnosis
5.2. Cancer Prevalence & Incidence Rate Globally with Key Countries
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/Long-term Impact)
6. Global Cancer Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Tumor Biomarker Tests
6.3.1.1. Prostate Specific Antigen Tests
6.3.1.2. Circulating Tumor Cells (CTC) Tests
6.3.1.3. Alpha-fetoprotein (AFP) Tests
6.3.1.4. CA 19-9 Tests
6.3.1.5. CA 125 Tests
6.3.1.6. HER2
6.3.1.7. BRCA
6.3.1.8. KRAS
6.3.1.9. Others
6.3.2. Imaging
6.3.2.1. Magnetic Resonance Imaging (MRI) Scan
6.3.2.2. Positron Emission Tomography (PET) Scan
6.3.2.3. Computed Tomography (CT) Scan
6.3.2.4. Mammography
6.3.2.5. Others
6.3.3. Endoscopy
6.3.3.1. Colonoscopy
6.3.3.2. Bronchoscopy
6.3.3.3. Others
6.3.4. Biopsy
6.3.4.1. Bone Marrow Biopsy
6.3.4.2. Needle Biopsy
6.3.4.3. Endoscopic Biopsy
6.3.4.4. Others
6.4. Market Attractiveness Analysis, by Test Type
7. Global Cancer Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Lung Cancer
7.3.3. Colorectal Cancer
7.3.4. Prostate Cancer
7.3.5. Pancreatic Cancer
7.3.6. Blood Cancer
7.3.7. Ovarian Cancer
7.3.8. Melanoma
7.3.9. Other Cancers
7.4. Market Attractiveness Analysis, by Application
8. Global Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Ambulatory Surgical Centers
8.3.3. Diagnostic Laboratories
8.3.4. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Tumor Biomarker Tests
10.2.1.1. Prostate Specific Antigen Tests
10.2.1.2. Circulating Tumor Cells (CTC) Tests
10.2.1.3. Alpha-fetoprotein (AFP) Tests
10.2.1.4. CA 19-9 Tests
10.2.1.5. CA 125 Tests
10.2.1.6. HER2
10.2.1.7. BRCA
10.2.1.8. KRAS
10.2.1.9. Others
10.2.2. Imaging
10.2.2.1. Magnetic Resonance Imaging (MRI) Scan
10.2.2.2. Positron Emission Tomography (PET) Scan
10.2.2.3. Computed Tomography (CT) Scan
10.2.2.4. Mammography
10.2.2.5. Others
10.2.3. Endoscopy
10.2.3.1. Colonoscopy
10.2.3.2. Bronchoscopy
10.2.3.3. Others
10.2.4. Biopsy
10.2.4.1. Bone Marrow Biopsy
10.2.4.2. Needle Biopsy
10.2.4.3. Endoscopic Biopsy
10.2.4.4. Others
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Breast Cancer
10.3.2. Lung Cancer
10.3.3. Colorectal Cancer
10.3.4. Prostate Cancer
10.3.5. Blood Cancer
10.3.6. Pancreatic Cancer
10.3.7. Ovarian Cancer
10.3.8. Melanoma
10.3.9. Other Cancers
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Diagnostic Laboratories
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Tumor Biomarker Tests
11.2.1.1. Prostate Specific Antigen Tests
11.2.1.2. Circulating Tumor Cells (CTC) Tests
11.2.1.3. Alpha-fetoprotein (AFP) Tests
11.2.1.4. CA 19-9 Tests
11.2.1.5. CA 125 Tests
11.2.1.6. HER2
11.2.1.7. BRCA
11.2.1.8. KRAS
11.2.1.9. Others
11.2.2. Imaging
11.2.2.1. Magnetic Resonance Imaging (MRI) Scan
11.2.2.2. Positron Emission Tomography (PET) Scan
11.2.2.3. Computed Tomography (CT) Scan
11.2.2.4. Mammography
11.2.2.5. Others
11.2.3. Endoscopy
11.2.3.1. Colonoscopy
11.2.3.2. Bronchoscopy
11.2.3.3. Others
11.2.4. Biopsy
11.2.4.1. Bone Marrow Biopsy
11.2.4.2. Needle Biopsy
11.2.4.3. Endoscopic Biopsy
11.2.4.4. Others
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Breast Cancer
11.3.2. Lung Cancer
11.3.3. Colorectal Cancer
11.3.4. Prostate Cancer
11.3.5. Pancreatic Cancer
11.3.6. Ovarian Cancer
11.3.7. Blood Cancer
11.3.8. Melanoma
11.3.9. Other Cancers
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Diagnostic Laboratories
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Tumor Biomarker Tests
12.2.1.1. Prostate Specific Antigen Tests
12.2.1.2. Circulating Tumor Cells (CTC) Tests
12.2.1.3. Alpha-fetoprotein (AFP) Tests
12.2.1.4. CA 19-9 Tests
12.2.1.5. CA 125 Tests
12.2.1.6. HER2
12.2.1.7. BRCA
12.2.1.8. KRAS
12.2.1.9. Others
12.2.2. Imaging
12.2.2.1. Magnetic Resonance Imaging (MRI) Scan
12.2.2.2. Positron Emission Tomography (PET) Scan
12.2.2.3. Computed Tomography (CT) Scan
12.2.2.4. Mammography
12.2.2.5. Others
12.2.3. Endoscopy
12.2.3.1. Colonoscopy
12.2.3.2. Bronchoscopy
12.2.3.3. Others
12.2.4. Biopsy
12.2.4.1. Bone Marrow Biopsy
12.2.4.2. Needle Biopsy
12.2.4.3. Endoscopic Biopsy
12.2.4.4. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Breast Cancer
12.3.2. Lung Cancer
12.3.3. Colorectal Cancer
12.3.4. Prostate Cancer
12.3.5. Pancreatic Cancer
12.3.6. Ovarian Cancer
12.3.7. Blood Cancer
12.3.8. Melanoma
12.3.9. Other Cancers
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Diagnostic Laboratories
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Tumor Biomarker Tests
13.2.1.1. Prostate Specific Antigen Tests
13.2.1.2. Circulating Tumor Cells (CTC) Tests
13.2.1.3. Alpha-fetoprotein (AFP) Tests
13.2.1.4. CA 19-9 Tests
13.2.1.5. CA 125 Tests
13.2.1.6. HER2
13.2.1.7. BRCA
13.2.1.8. KRAS
13.2.1.9. Others
13.2.2. Imaging
13.2.2.1. Magnetic Resonance Imaging (MRI) Scan
13.2.2.2. Positron Emission Tomography (PET) Scan
13.2.2.3. Computed Tomography (CT) Scan
13.2.2.4. Mammography
13.2.2.5. Others
13.2.3. Endoscopy
13.2.3.1. Colonoscopy
13.2.3.2. Bronchoscopy
13.2.3.3. Others
13.2.4. Biopsy
13.2.4.1. Bone Marrow Biopsy
13.2.4.2. Needle Biopsy
13.2.4.3. Endoscopic Biopsy
13.2.4.4. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Breast Cancer
13.3.2. Lung Cancer
13.3.3. Colorectal Cancer
13.3.4. Prostate Cancer
13.3.5. Melanoma
13.3.6. Pancreatic Cancer
13.3.7. Blood Cancer
13.3.8. Ovarian Cancer
13.3.9. Other Cancers
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Diagnostic Laboratories
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Tumor Biomarker Tests
14.2.1.1. Prostate Specific Antigen Tests
14.2.1.2. Circulating Tumor Cells (CTC) Tests
14.2.1.3. Alpha-fetoprotein (AFP) Tests
14.2.1.4. CA 19-9 Tests
14.2.1.5. CA 125 Tests
14.2.1.6. HER2
14.2.1.7. BRCA
14.2.1.8. KRAS
14.2.1.9. Others
14.2.2. Imaging
14.2.2.1. Magnetic Resonance Imaging (MRI) Scan
14.2.2.2. Positron Emission Tomography (PET) Scan
14.2.2.3. Computed Tomography (CT) Scan
14.2.2.4. Mammography
14.2.2.5. Others
14.2.3. Endoscopy
14.2.3.1. Colonoscopy
14.2.3.2. Bronchoscopy
14.2.3.3. Others
14.2.4. Biopsy
14.2.4.1. Bone Marrow Biopsy
14.2.4.2. Needle Biopsy
14.2.4.3. Endoscopic Biopsy
14.2.4.4. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Breast Cancer
14.3.2. Lung Cancer
14.3.3. Colorectal Cancer
14.3.4. Prostate Cancer
14.3.5. Pancreatic Cancer
14.3.6. Ovarian Cancer
14.3.7. Blood Cancer
14.3.8. Melanoma
14.3.9. Other Cancers
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Ambulatory Surgical Centers
14.4.3. Diagnostic Laboratories
14.4.4. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Agilent Technologies, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Applied DNA Sciences
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Becton, Dickinson and Company
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. bioMérieux SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Eli Lilly and Company
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Exact Sciences Corporation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. F. Hoffmann-La Roche Ltd.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. General Electric Company
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Hologic, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Illumina, Inc.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Menarini Silicon Biosystems
15.3.12.1. Company Overview
15.3.12.2. Product Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. QIAGEN
15.3.13.1. Company Overview
15.3.13.2. Product Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Siemens Healthcare GmbH
15.3.14.1. Company Overview
15.3.14.2. Product Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
15.3.15. Thermo Fisher Scientific, Inc.
15.3.15.1. Company Overview
15.3.15.2. Product Portfolio
15.3.15.3. SWOT Analysis
15.3.15.4. Financial Overview
15.3.15.5. Strategic Overview

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のがん診断市場2022年-2031年：検査種類別（腫瘍バイオマーカー検査、画像診断、内視鏡検査、生体検査）、エンドユーザー別(Cancer Diagnostics Market (Test Type: Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy; End-user: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のがん診断市場2022年-2031年：検査種類別（腫瘍バイオマーカー検査、画像診断、内視鏡検査、生体検査）、エンドユーザー別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp